Efavirenz, Lamivudine And Tenofovir Disoproxil Fumarate has 34 known drug interactions based on U.S. FDA drug labeling data. Of these, 2 are contraindicated combinations that should be avoided entirely. 1 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Elbasvir, Grazoprevir, Posaconazole. Patients taking Efavirenz, Lamivudine And Tenofovir Disoproxil Fumarate should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 34
- Contraindicated
- 2
- Major
- 1
- Moderate
- 11
Contraindicated (2)
- Efavirenz, Lamivudine And Tenofovir Disoproxil Fumarate + Elbasvir— Hepatitis C antiviral agents: Boceprevir Elbasvir/Grazoprevir Pibrentasvir/Glecaprevir Simeprevir Velpatasvir/Sofosbuvir…
- Efavirenz, Lamivudine And Tenofovir Disoproxil Fumarate + Grazoprevir— Hepatitis C antiviral agents: Boceprevir Elbasvir/Grazoprevir Pibrentasvir/Glecaprevir Simeprevir Velpatasvir/Sofosbuvir…
Major (1)
- Efavirenz, Lamivudine And Tenofovir Disoproxil Fumarate + Posaconazole— Posaconazole ↓ posaconazole Avoid concomitant use unless the benefit outweighs the risks.
Moderate (11)
- Efavirenz, Lamivudine And Tenofovir Disoproxil Fumarate + Acyclovir— Coadministration may increase concentrations of tenofovir and/or acyclovir due to competition for active tubular secreti…
- Efavirenz, Lamivudine And Tenofovir Disoproxil Fumarate + Cidofovir— Coadministration may increase concentrations of tenofovir and/or cidofovir due to competition for active tubular secreti…
- Efavirenz, Lamivudine And Tenofovir Disoproxil Fumarate + Ganciclovir— Coadministration may increase concentrations of tenofovir and/or ganciclovir due to competition for active tubular secre…
- Efavirenz, Lamivudine And Tenofovir Disoproxil Fumarate + Gentamicin— Coadministration may increase concentrations of tenofovir and/or gentamicin due to competition for active tubular secret…
- Efavirenz, Lamivudine And Tenofovir Disoproxil Fumarate + Ledipasvir— Ledipasvir/Sofosbuvir ↑ TDF Monitor for adverse reactions associated with TDF.
- Efavirenz, Lamivudine And Tenofovir Disoproxil Fumarate + Phenobarbital— Induction of CYP3A activity by phenobarbital may increase clearance of efavirenz resulting in lowered plasma concentrati…
- Efavirenz, Lamivudine And Tenofovir Disoproxil Fumarate + Rifabutin— Induction of CYP3A activity by rifabutin may increase clearance of efavirenz resulting in lowered plasma concentrations.
- Efavirenz, Lamivudine And Tenofovir Disoproxil Fumarate + Rifampin— Induction of CYP3A activity by rifampin may increase clearance of efavirenz resulting in lowered plasma concentrations.
- Efavirenz, Lamivudine And Tenofovir Disoproxil Fumarate + Sofosbuvir— Velpatasvir/Sofosbuvir ↓ velpatasvir Coadministration of EFV and sofosbuvir/velpatasvir is not recommended because it ma…
- Efavirenz, Lamivudine And Tenofovir Disoproxil Fumarate + Valacyclovir— Coadministration may increase concentrations of tenofovir and/or valacyclovir due to competition for active tubular secr…
- Efavirenz, Lamivudine And Tenofovir Disoproxil Fumarate + Valganciclovir— Coadministration may increase concentrations of tenofovir and/or valganciclovir due to competition for active tubular se…